scholarly journals Improved Outcomes in Patients With Large, High-Grade Extremity Soft Tissue Sarcoma Treated With Mesna-Ifosfamide Doxorubicin (MAI) Neoadjuvant Chemotherapy and Interdigitated Radiation Therapy Followed by Resection and 3 More Cycles of MAI

2016 ◽  
Vol 96 (2) ◽  
pp. S24 ◽  
Author(s):  
N. Sen ◽  
M. Batus ◽  
E.B. Jeans ◽  
L. Miller ◽  
S. Gitelis ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Soft Tissue ◽  
Neoadjuvant Chemotherapy ◽  
Soft Tissue Sarcoma ◽  
High Grade ◽  
Extremity Soft Tissue Sarcoma ◽  
Improved Outcomes

scholarly journals Histologic Alterations from Neoadjuvant Chemotherapy in High‐Grade Extremity Soft Tissue Sarcoma: Clinicopathological Correlation

2008 ◽  
Vol 13 (4) ◽  
pp. 451-458 ◽  
Author(s):  
David R. Lucas ◽  
Malti P. Kshirsagar ◽  
J. Sybil Biermann ◽  
Merlin R. Hamre ◽  
Dafydd G. Thomas ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Neoadjuvant Chemotherapy ◽  
Soft Tissue Sarcoma ◽  
High Grade ◽  
Clinicopathological Correlation ◽  
Extremity Soft Tissue Sarcoma

Neoadjuvant Chemotherapy, Radiation, and Limited Surgery for High Grade Soft Tissue Sarcoma of the Extremity

1988 ◽  
pp. 115-122 ◽  
Author(s):  
Frederick Eilber ◽  
Armando Giuliano ◽  
James Huth ◽  
Joseph Mirra ◽  
Gerald Rosen ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Neoadjuvant Chemotherapy ◽  
Soft Tissue Sarcoma ◽  
High Grade ◽  
Limited Surgery

scholarly journals Patient’s quality of life after surgery and radiotherapy for extremity soft tissue sarcoma - a retrospective single-center study over ten years

2019 ◽  
Vol 17 (1) ◽  
Author(s):  
Rebekka Götzl ◽  
Sebastian Sterzinger ◽  
Sabine Semrau ◽  
Nikolaos Vassos ◽  
Werner Hohenberger ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Radiation Therapy ◽  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Major Complication ◽  
Neoadjuvant Radiochemotherapy ◽  
Complication Rates ◽  
Extremity Soft Tissue Sarcoma ◽  
Disease Free

Abstract Background and objectives The purpose of this study is to analyze major complication rates and different aspects of health-related quality of life (HRQoL) in extremity soft tissue sarcoma (STS) patients treated with or without radio (chemo) therapy and surgery. Methods We performed a retrospective analysis of all patients who underwent Extremity STS excision from 2004 to 2014 (182 patients included). Patients’ data were collected from patients’ records. HRQoL was assessed by using EORTC QLQ-C30. Results A total of 182 patients underwent sarcoma resection. After neoadjuvant radiochemotherapy (RCT), the major-complication rate amounted to 28% (vs. 7%, no radiotherapy, p <  0.001). Major-complication rates after adjuvant radiotherapy (RT) occurred in 8% (vs. 7%, no radiotherapy, p = 0.265). Comparison QoL scores between treating with neoadjuvant RCT or without RT revealed significant worse scores with neoadjuvant RCT. Further stratification of disease control of these patients showed significant reduced scores in the group of disease-free patients with neoadjuvant RCT compared to irradiated disease-free patients. Discussion To date, there have only been a few investigations of QoL in STS. Retrospective study on quality of life have limitations, like a lack of baseline evaluation of QoL. Patient candidated to radiation therapy could have had worse QoL baseline due to more advanced disease. Disease status of the patients who answered the questionnaires could have been an influence of QoL and we could show reduced scores in the group of disease-free patients with neoadjuvant RCT, but not for the patients with recurrence or metastasis, so it is very hard to discriminate whether radiation therapy could really have an impact or not. Conclusion This study might assist in further improving the understanding of QoL in STS patients and may animate for prospective studies examining the oncological therapies impact on HRQoL.

Management of small, high-grade extremity soft tissue sarcoma

1999 ◽  
Vol 8 (4) ◽  
pp. 215-218 ◽  
Author(s):  
Martin R. Weiser ◽  
Jonathan J. Lewis ◽  
Denis H.Y. Leung ◽  
Murray F. Brennan
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
High Grade ◽  
Extremity Soft Tissue Sarcoma

scholarly journals Use of positron emission tomography in localized extremity soft tissue sarcoma treated with neoadjuvant chemotherapy

Cancer ◽  
2005 ◽  
Vol 103 (2) ◽  
pp. 339-348 ◽  
Author(s):  
Scott M. Schuetze ◽  
Brian P. Rubin ◽  
Cheryl Vernon ◽  
Douglas S. Hawkins ◽  
James D. Bruckner ◽  
...  
Keyword(s):  
Positron Emission Tomography ◽  
Soft Tissue ◽  
Neoadjuvant Chemotherapy ◽  
Soft Tissue Sarcoma ◽  
Emission Tomography ◽  
Positron Emission ◽  
Extremity Soft Tissue Sarcoma

Risk assessment in high grade sarcoma patients during neoadjuvant chemotherapy using multiple tracer PET

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 20006-20006
Author(s):  
J. F. Eary ◽  
E. Conrad ◽  
J. Link ◽  
A. Cizik ◽  
D. Mankoff ◽  
...  
Keyword(s):  
Drug Resistance ◽  
Soft Tissue ◽  
Neoadjuvant Chemotherapy ◽  
Soft Tissue Sarcoma ◽  
Pet Imaging ◽  
Cellular Proliferation ◽  
Soft Tissue Sarcomas ◽  
Response To Treatment ◽  
High Grade ◽  
Hypoxic Volume

20006 Background: Patients with high grade soft tissue sarcomas are treated with neoadjuvant chemotherapy. Sarcomas have biological features that may predict for poor outcome. Some of these features are tumor proliferation rate, level of tumor hypoxia, and upregulation of tumor drug resistance mechanisms. Methods: We have a group of specific PET imaging agents to quantify the level of activity of these tumor processes. Patients with soft tissue sarcomas receive [C-11]Thymidine (TdR) to assess cellular proliferation, [O-15] Water to quantify tumor blood flow and to serve as the input function for quantification of the other tracers, [C-11]Verapamil to assess drug resistance mechanism activity, and [F-18]Fluoromisonidazole) FMISO to quantify changes in tumor hypoxic volume in response to treatment. These studies are performed in a single PET imaging session prior to neoadjuvant chemotherapy, after the second of four cycles of therapy and in the week prior to resection. Results: An example of this complex study result, is demonstrated by a recent patient with a high grade soft tissue sarcoma. The tumor showed increased TdR uptake, a moderate hypoxic volume, and [C-11] verapamil uptake prior to initiation of neoadjuvant adriamycin based chemotherapy. After 2 cycles of therapy, there was a significant decrease in the maximum level and volume of TdR uptake and a large reduction in tumor hypoxic volume. Conclusions: These data would imply a high risk soft tissue sarcoma due the presence of increased cellular proliferation, a significant hypoxic volume and the absence of p-glycoprotein activity determined by the presence of [C-11]Verapamil uptake. However, early response is also suggested by the findings above. Patient outcome will be assessed and correlated with these tumor parameters to further understand what tumor biological risk factors can be quantified non-invasively and repeated throughout the clinical course in soft tissue sarcoma patients. Supported by NIH NCI PO1 42045–18 and S10 RR017229–01 [Table: see text] No significant financial relationships to disclose.

Sign in / Sign up

Export Citation Format

Share Document